Candesartan cilexetil/hydrochlorothiazide - Takeda

Drug Profile

Candesartan cilexetil/hydrochlorothiazide - Takeda

Alternative Names: Atacand HCT; Atacand Plus; Blopress Plus; CoKenzen; ECARD HD; ECARD LD; Parapres Plus 32; Parapres Plus Forte; TCV-116C

Latest Information Update: 26 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer AstraZeneca; Takeda
  • Class Antihypertensives; Benzimidazoles; Benzothiadiazines; Biphenyl compounds; Heart failure therapies; Tetrazoles
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 24 Jul 2018 Cheplapharm Arzneimittel acquires commercial rights to candesartan cilexetil/hydrochlorothiazide for Hypertension in Europe
  • 10 Dec 2012 Launched for Hypertension in Brazil (PO)
  • 10 Dec 2012 Launched for Hypertension in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top